 |
Endocyte Appoints Scot L. Harper, Ph.D., as Vice President of Clinical Operations
May 7, 2013
|
13.1 KB |
|
| |
WEST LAFAYETTE, Ind., May 7, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that Scot L. Harper, Ph.D., has been appointed as vice president o...
|
|
Endocyte Reports First Quarter 2013 Financial Results and Business Update
May 2, 2013
|
23.4 KB |
|
| |
Preparing for Potential Commercialization in Europe and Expanding SMDC Pipeline
Conference call today at 4:30 p.m. EDT
WEST LAFAYETTE, Ind., May 2, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for person...
|
|
Clinical Study Shows Involvement of Activated Macrophages in Osteoarthritis, Identified by Endocyte's Etarfolatide
Apr 25, 2013
|
14.5 KB |
|
| |
Etarfolatide Differentiates Inflammatory from Non-Inflammatory Disease States in Osteoarthritis Patients
Data Presented at the OARSI 2013 World Congress on Osteoarthritis
PHILADELPHIA, April 25, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDC...
|
|
Endocyte, Inc. Announces Annual Stockholders' Meeting
Apr 22, 2013
|
11.2 KB |
|
| |
WEST LAFAYETTE, Ind., April 22, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that it will hold its 2013 Annual Meeting of Stockholders on We...
|
|
Endocyte Announces First Quarter 2013 Earnings Conference Call
Apr 18, 2013
|
11.9 KB |
|
| |
WEST LAFAYETTE, Ind., April 18, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company will host a conference call on Thursday, May 2...
|
|
Endocyte Announces Presentations at AACR Annual Meeting 2013
Apr 3, 2013
|
16.6 KB |
|
| |
WEST LAFAYETTE, Ind., April 3, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that four poster presentations will be presented by Endocyte sci...
|
|
Endocyte to Present at the Future Leaders in the Biotech Industry Conference
Apr 1, 2013
|
12.0 KB |
|
| |
WEST LAFAYETTE, Ind., April 1, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that Ron Ellis, president and CEO of Endocyte, will present at t...
|
|
Endocyte to Webcast Investor and Analyst Day in New York City
Mar 18, 2013
|
12.1 KB |
|
| |
WEST LAFAYETTE, Ind., March 18, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced the company's management team will host an Investor and Analyst...
|
|
Endocyte's Investigational Diagnostic Imaging Agent Etarfolatide Identifies Ovarian Cancer and Non-Small Cell Lung Cancer Patients Most Likely to Benefit From Folate Receptor-Targeted Treatment, New Analysis Shows
Mar 1, 2013
|
20.9 KB |
|
| |
Patients With 100 Percent Folate Receptor-Positive Tumor Lesions Experienced Substantial Progression-Free Survival When Treated With Vintafolide
New Data Presented at AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy
SAN DIEGO, March 1, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECY...
|
|
Endocyte to Present at Upcoming Conferences in March
Feb 26, 2013
|
12.6 KB |
|
| |
WEST LAFAYETTE, Ind., Feb. 26, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the following...
|
|
Endocyte Reports Fourth Quarter and Year End 2012 Financial Results and Business Update
Feb 25, 2013
|
26.6 KB |
|
| |
- Endocyte and Merck Expand Vintafolide Development -
- EMA Approval Decision for Vintafolide Expected by Year-End 2013 -
- Conference call today at 4:30 p.m. EST -
WEST LAFAYETTE, Ind., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conju...
|
|
Endocyte to Present at Upcoming Conferences
Feb 7, 2013
|
11.9 KB |
|
| |
WEST LAFAYETTE, Ind., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the following ...
|
|
Endocyte Announces Fourth Quarter and Full Year 2012 Earnings Conference Call
Feb 6, 2013
|
13.0 KB |
|
| |
WEST LAFAYETTE, Ind., Feb. 6, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company will host a conference call on Monday, Feb. 25, at 4:30 p.m. EST to discuss its fourt...
|
|
Endocyte to Advance Development of EC1069, a PSMA-Targeted Small Molecule Drug Conjugate Therapy for Prostate Cancer
Jan 29, 2013
|
14.4 KB |
|
| |
Company Expects to File IND for Therapeutic Agent in 2013
Human Study of Companion Imaging Agent EC0652 Demonstrates Safety and Binding Specificity
WEST LAFAYETTE, Ind., Jan. 29, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion...
|
|
Dr. Lesley Russell Joins the Endocyte Board of Directors
Jan 8, 2013
|
13.1 KB |
|
| |
WEST LAFAYETTE, Ind., Jan. 8, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced Lesley Russell, M.B.Ch.B., has joined the Endocyte board of direc...
|
|
Merck and Endocyte Announce Acceptance for Review of European Marketing Authorization Applications for Vintafolide and Companion Diagnostic Etarfolatide for Folate-Receptor Positive Platinum-Resistant Ovarian Cancer
Nov 27, 2012
|
19.4 KB |
|
| |
Novel personalized treatment approach targets folate receptors on
cancer cells
WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--
Merck, known as MSD outside the United States and Canada (NYSE: MRK),
and Endocyte Inc. (NASDAQ: ECYT), today announced that the European
...
|
|
Endocyte to Present at Upcoming Healthcare Conferences
Nov 6, 2012
|
11.8 KB |
|
| |
WEST LAFAYETTE, Ind., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that management will present at the following upcoming conference...
|
|
Endocyte Reports Third Quarter 2012 Financial Results and Business Update
Nov 1, 2012
|
24.4 KB |
|
| |
- MAA Filing Process for Vintafolide and Etarfolatide on Schedule for Completion by Year-End 2012 -
- Conference call today at 4:30 EDT -
WEST LAFAYETTE, Ind., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging d...
|
|
Endocyte Announces Third Quarter 2012 Earnings Conference Call
Oct 25, 2012
|
11.5 KB |
|
| |
WEST LAFAYETTE, Ind., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company will host a conference call on Thursday, Nov. 1, at 4:30 p.m. EDT, to discuss its th...
|
|
Data Published Identify the Folate Receptor as a Potential Biomarker for Targeted Therapies in a Majority of Lung Cancers
Oct 12, 2012
|
14.8 KB |
|
| |
- Results Show 72 Percent of Adenocarcinomas and 51 Percent of Squamous Cell Carcinoma of the Lung Express Folate Receptor -
- Data Published in Archives of Pathology & Laboratory Medicine -
WEST LAFAYETTE, Ind., Oct. 12, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small mol...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter
